Skip to menu Skip to content Skip to footer
Dr

Amirah Etchegaray

Email: 

Overview

Availability

Dr Amirah Etchegaray is:
Available for supervision

Research interests

  • Inflammatory Bowel Disease

Works

Search Professor Amirah Etchegaray’s works on UQ eSpace

10 works between 2023 and 2025

1 - 10 of 10 works

2025

Journal Article

The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring

Gilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's & Colitis 360, 7 (2) otaf028. doi: 10.1093/crocol/otaf028

The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring

2025

Journal Article

Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study

Etchegaray, Amirah, Mudaliar, Sanjivan, Ryan, Kimberley, Hay, Karen, Hwang, Jason, Devereaux, Benedict, Appleyard, Mark and Grimpen, Florian (2025). Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study. Internal Medicine Journal, 55 (3), 435-443. doi: 10.1111/imj.16652

Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study

2025

Journal Article

Endosonographically confirmed Type III Choledochal Cyst Managed with Endoscopic Needle Knife Division

Etchegaray, Amirah, Mudaliar, Sanjivan and Devereaux, Benedict (2025). Endosonographically confirmed Type III Choledochal Cyst Managed with Endoscopic Needle Knife Division. VideoGIE. doi: 10.1016/j.vgie.2025.03.035

Endosonographically confirmed Type III Choledochal Cyst Managed with Endoscopic Needle Knife Division

2025

Journal Article

Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series

Etchegaray, Amirah, Tambakis, George, Kumar, Rina, Croft, Anthony, Radford-Smith, Graham and Walker, Gareth J. (2025). Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series. Therapeutic Advances in Gastroenterology, 18, 1-14. doi: 10.1177/17562848251323511

Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series

2024

Conference Publication

Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series

Swe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series

2024

Conference Publication

Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis

Etchegaray, Amirah, Tambakis, George, Croft, Anthony, Radford-Smith, Graham and Walker, Gareth (2024). Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis

2023

Conference Publication

Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study

Anandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study

2023

Conference Publication

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

2023

Conference Publication

Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report

Etchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report

2023

Conference Publication

Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study

Etchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study

Supervision

Availability

Dr Amirah Etchegaray is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Dr Amirah Etchegaray's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au